Sympazan Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Mechanism of Action
Sympazan Indications
Indications
Sympazan Dosage and Administration
Adults and Children
Sympazan Contraindications
Not Applicable
Sympazan Boxed Warnings
Boxed Warning
Sympazan Warnings/Precautions
Warnings/Precautions
Increased risk of drug-related mortality from concomitant use with opioids. Monitor for somnolence or sedation. Monitor for signs/symptoms of serious skin reactions (eg, SJS, TEN), esp. during the first 8 weeks of initiation or when re-introducing therapy; discontinue at the first sign of rash unless it's not drug-related. Evaluate immediately if signs or symptoms of drug reaction with eosinophilia and systemic symptoms (DRESS)/multiorgan hypersensitivity develop; discontinue if alternative etiology cannot be established. Monitor for the emergence or worsening of depression, suicidal thoughts/behavior, and/or unusual changes in mood or behavior. Assess patient's risk for abuse, misuse, addiction prior to and during therapy. Avoid abrupt cessation; taper by decreasing total daily dose by 5–10mg/day on a weekly basis. Drug or alcohol abusers. Severe renal or hepatic impairment or ESRD. Elderly. Neonatal sedation and withdrawal syndrome; monitor neonates exposed during pregnancy or labor. Pregnancy (esp. late stage). Nursing mothers: monitor infants.
Sympazan Pharmacokinetics
Absorption
After single-dose administration, the time to peak concentrations (Tmax) of clobazam oral film under fasted conditions ranged from 0.33 to 4.0 hours.
Distribution
The volume of distribution at steady state was ~100 L. The in vitro plasma protein binding of clobazam and N-desmethylclobazam is ~80-90% and 70%, respectively.
Elimination
Renal (82%), fecal (11%).
Sympazan Interactions
Interactions
Sympazan Adverse Reactions
Adverse Reactions
Sympazan Clinical Trials
See Literature
Sympazan Note
Notes
Sympazan Patient Counseling
See Literature